Lancet Neurology

Papers
(The H4-Index of Lancet Neurology is 84. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Multidisciplinary care for amyotrophic lateral sclerosis958
Correction to Lancet Neurol 2021; 20: 448–59863
Correction to Lancet Neurol 2024; 23: 168–77822
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease707
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study635
Anti-CD19 CAR T cells for refractory myasthenia gravis506
Management of atherosclerotic extracranial carotid artery stenosis501
A biological classification of Huntington's disease: the Integrated Staging System469
Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, r459
RAB32 mutation in Parkinson's disease439
Correction to Lancet Neurol 2025; 24: 850–65409
Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study394
The relevance of social and commercial determinants for neurological health361
Traumatic brain injury research: homogenising heterogeneity347
Treatment-induced neuropathy of diabetes: an underdiagnosed entity – Authors' reply337
Increasing diversity in dementia research335
The predictive value and clinical use of the neurological pupillary index – Authors' reply324
Dementia diagnosis in the anti-amyloid era289
Lessons and future directions for GBA1-targeting therapies279
Correction to Lancet Neurol 2022; 21: 42–52259
The East Asian Parkinson Disease Genomics Consortium245
New therapies for Pompe disease: are we closer to a cure?232
Implications of the KIWE trial for low-income and lower-middle-income countries230
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study230
Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial229
Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study227
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial212
Global burden of stroke: dynamic estimates to inform action196
Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study191
Surrogate endpoints for progressive multifocal leukoencephalopathy181
The prescription of valproate: risk of harm176
Diana Cejas175
The Genetic Epidemiology of Parkinson's Disease view – Authors' reply172
Considering the neurological health needs of LGBTQIA people171
Safe laboratory management of prions and proteopathic seeds168
Elia M Pestana Knight167
Movement disorders research in 2021: cracking the paradigm167
Beyond the modular brain158
Aspiring to restore arm and hand function after stroke155
Albert Kwaku Akpalu153
A sensitive portrayal of a controversial condition150
A chilly tale of dementia146
A nasal CGRP receptor antagonist for acute migraine therapy145
A study in healing the wounds of trauma143
Trials in intracerebral haemorrhage: a path to success?141
Correction to Lancet Neurol 2023; 22: 812–25141
Gene therapy for X-linked myotubular myopathy: the challenges140
Parkinson's disease is a recognisable and useful diagnostic entity135
Delving into the human mind133
Correction to Lancet Neurol 2022; 21: 284–94130
Neuropathology of Alzheimer's disease after anti-amyloid β antibody treatment128
Epilepsy syndromes: an essential piece of the puzzle125
Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial120
Complex regional pain syndrome: advances in epidemiology, pathophysiology, diagnosis, and treatment115
Development of treatments for Down syndrome115
Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm tri114
From stroke awareness to stroke action awareness113
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised contro112
Intracranial pressure monitoring with and without brain tissue oxygen pressure monitoring for severe traumatic brain injury in France (OXY-TC): an open-label, randomised controlled superiority trial111
Amyotrophic lateral sclerosis from genotoxins alone?110
Functional or hysterical?109
Cognitive function in people with functional seizures109
B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases109
Revisiting candesartan: new evidence for an old option in migraine prevention108
Changing multiple-sclerosis-induced thoughts and behaviours106
Supporting young carers across neurological disorders105
Learning to be an adult with a disability104
α-synuclein seed amplification and its uses in Parkinson's disease102
Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial100
Effect of blood pressure-lowering agents on microvascular function in people with small vessel diseases (TREAT-SVDs): a multicentre, open-label, randomised, crossover trial98
Rethinking AI trials in brain health97
A proposal for equity neuroscience97
The ATTeST trial in ataxia telangiectasia: some concerns – Authors' response95
Safety and efficacy of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia (ATTeST): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial94
Multiple sclerosis in 2022: old players, new insights93
A health literacy campaign for Parkinson's disease in Africa: a novel campaign to break down language barriers92
Riluzole and spinocerebellar ataxia type 2: the ATRIL trial91
Major advances in Parkinson's disease over the past two decades and future research directions89
New results for risdiplam in spinal muscular atrophy89
Expansion of stenting indications in the USA88
Responsible innovation in neurology87
Correction to Lancet Neurol 2022; 21: 620–3186
Correction to Lancet Neurol 2024; 23: 110–2286
Brain health in the Philippines84
0.28949308395386